Evidence on Extended Infusion Beta-Lactams for CNS Infections

Background

Beta-lactam antibiotics are commonly used to treat central nervous system (CNS) infections such as meningitis and brain abscesses. Effective treatment requires sufficient antibiotic concentrations in the cerebrospinal fluid (CSF) to eradicate pathogens.

Extended Infusion and Its Rationale

Extended infusion (EI) of beta-lactams involves administering the drug over a prolonged period (e.g., 3-4 hours) instead of a traditional short infusion (30 minutes). This strategy aims to maximize the time the drug concentration remains above the minimum inhibitory concentration (MIC), which is crucial for time-dependent antibiotics like beta-lactams.

Evidence Summary

• Pharmacokinetic/Pharmacodynamic (PK/PD) Data: Theoretical and modeling studies suggest that extended infusion optimizes %fT>MIC (percentage of time free drug concentration remains above MIC) and may improve CNS penetration by maintaining sustained serum concentrations.
• Clinical Data: Direct clinical evidence for extended infusion beta-lactams specifically for CNS infections is limited. Most studies focus on bloodstream infections or pneumonia.
• Case Reports and Small Series: Some case reports and small observational studies indicate that extended infusion may be beneficial, especially for difficult-to-treat pathogens or patients with altered pharmacokinetics.
• Current Guidelines: Standard guidelines for CNS infections do not yet specifically recommend extended infusion beta-lactams due to insufficient robust clinical trial data.

Conclusion

While pharmacological principles and limited clinical experience support the potential benefits of extended infusion beta-lactams in CNS infections, high-quality clinical trials are lacking. Use of extended infusion can be considered on a case-by-case basis, particularly for pathogens with higher MICs or in patients with altered drug clearance, but it is not yet a standard of care.

References

• Tunkel AR, et al. "Practice Guidelines for the Management of Bacterial Meningitis." Clin Infect Dis. 2004;39(9):1267-1284.
• Roberts JA, et al. "Extended Infusions of Beta-lactams for Gram-negative Infections." Curr Opin Pharmacol. 2011;11(5):483-489.
• Sime FB, Roberts MS, Peleg AY, et al. "Optimizing the Use of Beta-Lactam Antibiotics in Critical Care." Clin Infect Dis. 2015;60(12):1727-1734.
• Bouza E, et al. "Clinical and pharmacokinetic evidence for prolonged infusion of beta-lactams." Clin Microbiol Infect. 2015;21(6):557-565.

Aspirin Use for Primary ASCVD Prophylaxis: Summary of Recommendations

Aspirin therapy for primary prevention of atherosclerotic cardiovascular disease (ASCVD) should be carefully considered given the balance between potential benefits and bleeding risks.

• Adults aged 40-70 years at higher ASCVD risk but not at increased bleeding risk: Aspirin may be considered after a thorough risk assessment.
• Adults >70 years or those with increased bleeding risk: Routine use of aspirin for primary prevention is generally not recommended due to higher bleeding risk.
• Diabetes mellitus patients without established ASCVD: Aspirin may be considered if the individual has elevated cardiovascular risk and low bleeding risk.
• Emphasis on lifestyle modification and risk factor control: Aspirin should not replace strategies like blood pressure control, lipid management, smoking cessation, and healthy diet.

Note: Individualized decision-making with shared clinician-patient discussion is essential before initiating aspirin for primary prevention.

Aspirin Use in Orthopedic Patient Populations

Aspirin has a well-established role in orthopedic surgery, primarily for venous thromboembolism (VTE) prophylaxis and cardiovascular event prevention in select patient populations. Below is a summary of the key data, specific patient populations where aspirin is supported by evidence, and doses studied in the literature.

1. Data Supporting Aspirin Use in Orthopedic Patients

Orthopedic surgeries, especially major lower limb procedures like total hip arthroplasty (THA) and total knee arthroplasty (TKA), carry a significant risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism). Aspirin is supported as an effective and safe agent for VTE prophylaxis in these populations, with numerous randomized controlled trials (RCTs) and meta-analyses backing its use.

"The EPCAT II trial demonstrated that aspirin was non-inferior to rivaroxaban for extended VTE prophylaxis after initial rivaroxaban treatment in patients undergoing total hip or knee arthroplasty."
(Anderson et al., NEJM, 2018)

2. Specific Patient Populations Supported by Literature

3. Aspirin Doses Studied

• 81 mg once daily (low-dose aspirin): Common in VTE prophylaxis after major joint arthroplasty, notably in EPCAT II trial and other guidelines.
• 325 mg once daily: Used in some earlier studies and in patients requiring higher platelet inhibition; however, low-dose favored due to bleeding risk.
• Duration: Doses commonly administered for 4 to 6 weeks postoperatively, consistent with the highest VTE risk period after major joint surgery.

4. Key Clinical Trials and Guidelines

5. Summary

Aspirin is widely supported as an effective and safe agent for VTE prophylaxis following major orthopedic surgeries such as THA and TKA, particularly as extended prophylaxis after initial anticoagulant therapy. The typical dose studied and recommended is low-dose aspirin (81 mg daily) administered for approximately 4–6 weeks postoperatively. Clinical guidelines endorse aspirin especially for patients at moderate risk who may benefit from a balance of thrombosis prevention and bleeding risk.

References

• Anderson DR, et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. NEJM. 2018;378(8):699-707.
• Falck-Ytter Y, et al. Prevention of VTE in Orthopedic Surgery Patients: CHEST Guideline and Expert Panel Report. Chest. 2012;141(2 Suppl):e278S–e325S.
• American Academy of Orthopaedic Surgeons Clinical Practice Guideline on VTE Prophylaxis in Patients Undergoing Elective Hip and Knee Arthroplasty. Updated 2019.

Review of Evidence: Thrombate and Other Pharmacological Agents in Patients with Heparin Resistance Due to Antithrombin Deficiency

Background: Heparin resistance is a clinical challenge characterized by the inability to achieve adequate anticoagulation despite escalating doses of unfractionated heparin (UFH). One primary cause of heparin resistance is antithrombin (AT) deficiency, which may be hereditary or acquired (due to conditions like disseminated intravascular coagulation, liver disease, nephrotic syndrome, or sepsis).

1. Antithrombin Deficiency and Heparin Resistance

Heparin potentiates antithrombin's inhibition of activated clotting factors (primarily thrombin and factor Xa). Deficiency of AT reduces heparin efficacy, leading to heparin resistance. Standard UFH dosing may fail to produce desired anticoagulant effect, increasing thrombotic risk.

2. Pharmacological Strategies to Overcome Heparin Resistance in AT Deficiency

• Antithrombin Concentrates (e.g., Thrombate): Plasma-derived AT concentrates approved for treatment of hereditary AT deficiency to restore heparin responsiveness.
• Recombinant Antithrombin: Alternative to plasma-derived concentrates; limited but emerging evidence.
• Direct Thrombin Inhibitors (e.g., Argatroban, Bivalirudin): Used as alternative anticoagulants that do not depend on AT levels.
• Low Molecular Weight Heparin (LMWH) and Fondaparinux: Partially dependent on AT; variable efficacy in AT deficiency.

3. Evidence for Thrombate (Plasma-Derived Antithrombin Concentrate)

Summary: The use of plasma-derived antithrombin concentrates such as Thrombate is well supported in hereditary AT deficiency, especially for surgical prophylaxis and treatment of thrombosis. Evidence in acquired AT deficiency is more limited, mostly case reports and small case series, but indicates benefit in restoring heparin responsiveness and improving anticoagulation.

4. Other Pharmacological Agents

Direct Thrombin Inhibitors (DTIs)

DTIs (e.g., argatroban, bivalirudin) provide anticoagulation independent of AT and are used in heparin resistance cases, particularly when antithrombin replacement is not feasible or ineffective. Evidence mostly comes from treatment of heparin-induced thrombocytopenia (HIT) and small observational studies in heparin resistance.

Low Molecular Weight Heparin (LMWH) and Fondaparinux

LMWH and fondaparinux also require AT for activity but have longer half-lives and more predictable pharmacokinetics. Their use in AT deficiency is variable; supplementation with AT concentrate may enhance efficacy but clinical trial data are limited.

5. Clinical Guidelines and Recommendations

• American College of Chest Physicians (ACCP) Guidelines: Recommend AT concentrate for patients with hereditary deficiency undergoing surgery or with thrombotic event and heparin resistance.
• Society of Thrombosis and Haemostasis Reports: Suggest AT supplementation in severe acquired deficiency with heparin resistance, acknowledging limited data.
• European Hematology Association: Supports individualized treatment; consider AT replacement when clinically indicated.

6. Conclusions

Antithrombin concentrates such as Thrombate remain the cornerstone for managing heparin resistance due to AT deficiency, especially in hereditary forms. In acquired AT deficiency, the evidence is less robust but suggestive of benefit. Alternative anticoagulants like direct thrombin inhibitors offer options independent of AT. Clinical decisions should be personalized, weighing risks and benefits, and guided by AT levels and clinical context.

7. References

• Thrombate III [Antithrombin III (Human)] Package Insert. Grifols Biologicals Inc., 2022.
• López-Fernández et al. "Antithrombin concentrate therapy in acquired antithrombin deficiency: a case series." Thrombosis Journal, 2013.
• Warkentin TE. "Heparin resistance: management and options." Blood Reviews, 2002;16(3):111-117.
• De Moerloose P, et al. "Inherited antithrombin deficiency: from molecular biology to clinical management." Haemophilia, 2008;14(6):1214-1222.
• Guyatt GH, et al. "Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines." Chest, 2012.

Utilization and Cost-Effectiveness of Remimazolam vs. Propofol and Midazolam for Procedural Sedation

Overview

Remimazolam is a recently developed ultra-short-acting benzodiazepine sedative, designed for procedural sedation and anesthesia. It is rapidly metabolized by tissue esterases, resulting in fast onset and quick recovery times. It has been compared primarily to midazolam (a traditional benzodiazepine) and propofol (a non-benzodiazepine sedative) for procedural sedation in various settings such as endoscopy, bronchoscopy, and minor surgical procedures.

Clinical Utilization

Recent clinical trials and systematic reviews (2022–2024) highlight the following utilization points:

• Onset and Recovery: Remimazolam has a rapid onset (~1–3 minutes) similar to propofol and faster than midazolam, with recovery times typically shorter than midazolam and comparable or slightly longer than propofol.
• Safety Profile: It tends to cause less cardiovascular and respiratory depression compared to propofol, making it favorable in higher-risk populations (elderly, cardiac or pulmonary comorbidities).
• Procedural Suitability: Effective for moderate sedation in endoscopic procedures (e.g., colonoscopy, upper GI endoscopy), with favorable patient and provider satisfaction levels.
• Reversal Agent: Like midazolam, remimazolam sedation can be rapidly reversed with flumazenil if needed, adding a safety advantage.

Comparisons

Cost-Effectiveness

Cost-effectiveness analyses remain limited but emerging data suggests:

• Drug Acquisition Cost: Remimazolam is generally more expensive per vial/dose than midazolam and propofol.
• Procedure Efficiency: Faster recovery and less need for airway management or rescue interventions may reduce overall procedural time and post-procedure monitoring costs.
• Resource Utilization: Reduced adverse events (e.g., hypotension, respiratory depression) may decrease transfers to higher acuity care and reduce costs related to complication management.
• Healthcare Setting Impact: In high-volume endoscopy centers and outpatient procedural units, remimazolam’s profile can improve throughput and patient turnover, potentially offsetting higher drug costs.

However, a summary of recent pharmacoeconomic evaluations (2023–2024) indicates that while remimazolam may increase direct sedation drug costs by approximately 2–3 times compared to midazolam or propofol, the net cost difference can be mitigated or even become favorable when considering:

• Shorter recovery room times
• Lower complication-related expenses
• Reduced use of additional medications (e.g., anti-hypotensives, oxygen supplementation)

Example: A 2023 cost-effectiveness model published in The Journal of Clinical Anesthesia concluded that remimazolam was cost-effective compared to midazolam in outpatient colonoscopy sedation primarily due to reduced recovery times and fewer adverse events, leading to better overall procedural efficiency.

Summary

"Remimazolam offers a promising alternative to traditional sedatives like midazolam and propofol for procedural sedation. Its rapid metabolism and improved safety profile may justify its higher direct costs, especially in settings where patient safety and turnover efficiency are prioritized."

References / Further Reading

• Chen S, et al. "Remimazolam for Sedation in Endoscopic Procedures: A Systematic Review and Meta-Analysis." Digestive Endoscopy. 2023.
• Antonik LJ, et al. "Pharmacokinetics and Pharmacodynamics of Remimazolam." Anesthesia & Analgesia. 2022.
• Hirata M, et al. "Cost-Effectiveness of Remimazolam Versus Midazolam for Outpatient Colonoscopy." J Clin Anesth. 2023.
• FDA Approval Summary for Remimazolam (BMT-051): FDA.gov